Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

AKTS US Equity

Aktis Oncology, Inc.Health Care · Pharmaceutical Preparations · CIK 2035832 · FY ends Dec 31
$25.02
+0.02 (+0.08%)
USD · as of 2026-08-19 · marketstack
5 8-K filings · 4 13D · 1 13G
DateEventWhat happened / filerSource
2026-08-138-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-05-1413GSchedule 13G filed — ≥5% beneficial owner (passive) · by Blue Owl Capital Holdings LPsec.gov ↗
2026-05-118-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-04-168-K 7.01Regulation FD disclosuresec.gov ↗
2026-04-168-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
2026-03-308-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-01-2013DSchedule 13D filed — ≥5% beneficial owner (active intent) · by MPM BIOVENTURES 2018, L.P.sec.gov ↗
2026-01-2013DSchedule 13D filed — ≥5% beneficial owner (active intent) · by EcoR1 Capital, LLCsec.gov ↗
2026-01-1513DSchedule 13D filed — ≥5% beneficial owner (active intent) · by ELI LILLY & Cosec.gov ↗
2026-01-1413DSchedule 13D filed — ≥5% beneficial owner (active intent) · by VV Manager II, LLCsec.gov ↗
2026-01-128-K 5.03Amendments to articles of incorporation or bylaws; fiscal year changesec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-01-12

Every row is a filed document, checked against its EDGAR index.